OPGN - OpGen Corporation Total Debt to Capital

OpGen, Inc. (OPGN) specializes in the rapid analysis of resistant bacteria, where high-speed genetic screening provides a competitive advantage. This chart of current share prices reflects a total debt-to-equity ratio of 0.00. However, the business is in critical condition: operating cash flow has dried up and previously profitable assets have depreciated, creating a real risk of bankruptcy for the entity.

OpGen, Inc. (OPGN) possesses significant pricing power in the rapid sepsis diagnostics segment, enabling the company to effectively manage operating cash flow to service its obligations. By analyzing the debt-to-equity ratio, an investor assesses the degree of financial leverage, where total borrowings are compared against net assets to determine the business's reliance on external financing and the risks of over-indebtedness.